You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 10,112,981

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,112,981

Title:	Methods for treatment of stroke or cerebrovascular accidents using an ET.sub.B receptor agonist
Abstract:	Methods of using an ET.sub.B receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ET.sub.B receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.
Inventor(s):	Gulati; Anil (Naperville, IL)
Assignee:	MIDWESTERN UNIVERSITY (Downers Grove, IL)
Application Number:	15/352,238
Patent Claims:	1. A method of treating a stroke or cerebrovascular accident comprising administering multiple doses of a therapeutically effective amount of N-Succinyl-[Glu.sup.9, Ala.sup.11,15] Endothelin 1 to an individual in need thereof and further comprising administering a therapeutically effective amount of a second therapeutic agent useful in the treatment of stroke or cerebrovascular accident. 2. The method of claim 1 wherein the stroke or cerebrovascular accident is caused by thrombosis, embolism, or hemorrhage. 3. The method of claim 1 wherein the second therapeutic agent comprises a neuroprotective agent. 4. The method of claim 3 wherein the neuroprotective agent is selected from the group consisting of a thrombolytic agent, an erythropoiesis-stimulating agent, an ET.sub.A antagonist, an oxygen carrier, and mixtures thereof. 5. The method of claim 4 wherein the thrombolytic agent comprises tissue plasminogen activator. 6. The method of claim 4 wherein the erythropoiesis-stimulating agent is selected from the group consisting of erythropoietin, darbepoetin, epoetin alfa, and mixtures thereof. 7. The method of claim 4 wherein the oxygen carrier comprises a hemoglobin-based blood substitute, a perfluorocarbon-based blood substitute, or a mixture thereof. 8. The method of claim 4 wherein the ET.sub.A antagonist is selected from sulfosoxazole, clazosentan, atrasentan, tezosentan, bosentan, sitaxsentan, enrasentan, BMS 207940, BMS 193884, BMS 182874, J 104132, VML 588/Ro 61 1790, T-0115, TAK 044, BQ 788, TBC2576, TBC3214, PD180988, ABT 546, SB247083, RPR118031A, BQ123, and mixtures thereof. 9. The method of claim 3 wherein the neuroprotective agent is selected from the group consisting of argatroban, alfimeprase, tenecteplase, ancrod, sildenafil, insulin, insulin growth factor, magnesium sulfate, human serum albumin, caffeinol, microplasmin, a statin, eptifibatide, tinzaparin, enecadin, citicoline, edaravone, cilostazol, and mixtures thereof. 10. The method of claim 1 wherein the N-Succinyl-[Glu.sup.9, Ala.sup.11,15] Endothelin 1 and the second therapeutic agent are administered simultaneously. 11. The method of claim 10 wherein the N-Succinyl-[Glu.sup.9, Ala.sup.11,15] Endothelin 1 and the second therapeutic agent are administered from a single composition. 12. The method of claim 10 wherein the N-Succinyl-[Glu.sup.9, Ala.sup.11,15] Endothelin 1 and the second therapeutic agent are administered from separate compositions. 13. The method of claim 1 wherein the N-Succinyl-[Glu.sup.9, Ala.sup.11,15] Endothelin 1 and the second therapeutic agent are administered separately. 14. The method of claim 13 wherein the N-Succinyl-[Glu.sup.9, Ala.sup.11,15] Endothelin 1 is administered prior to the second therapeutic agent. 15. The method of claim 13 wherein the N-Succinyl-[Glu.sup.9, Ala.sup.11,15] Endothelin 1 is administered after the second therapeutic agent. 16. The method of claim 1 wherein the N-Succinyl-[Glu.sup.9, Ala.sup.11,15] Endothelin 1 is administered in an amount of about 0.005 to about 500 micrograms per dose. 17. The method of claim 1 wherein the N-Succinyl-[Glu.sup.9, Ala.sup.11,15] Endothelin 1 is administered in an amount of about 0.005 to about 50 micrograms per kilogram per min infusion. 18. The method of claim 1 wherein about 0.5 micrograms per kilogram (.mu.g/kg) of the N-Succinyl-[Glu.sup.9, Ala.sup.11,15] Endothelin 1 is administered intravenously per dose. 19. The method of claim 18 wherein the N-Succinyl-[Glu.sup.9, Ala.sup.11,15] Endothelin 1 is administered in three doses per day.

Details for Patent 10,112,981

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	06/01/1989	⤷ Try a Trial	2027-08-21
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234		⤷ Try a Trial	2027-08-21
Amgen, Inc.	PROCRIT	epoetin alfa	Injection	103234		⤷ Try a Trial	2027-08-21
Genentech, Inc.	TNKASE	tenecteplase	For Injection	103909	06/02/2000	⤷ Try a Trial	2027-08-21
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.